Skye Bioscience Statistics
Total Valuation
Skye Bioscience has a market cap or net worth of $24.95 million. The enterprise value is $7.10 million.
| Market Cap | 24.95M |
| Enterprise Value | 7.10M |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Skye Bioscience has 35.14 million shares outstanding. The number of shares has increased by 0.69% in one year.
| Current Share Class | 35.14M |
| Shares Outstanding | 35.14M |
| Shares Change (YoY) | +0.69% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 1.38% |
| Owned by Institutions (%) | 11.98% |
| Float | 22.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.65 |
| P/TBV Ratio | 2.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.78, with a Debt / Equity ratio of 0.03.
| Current Ratio | 1.78 |
| Quick Ratio | 1.65 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -79,087.51 |
Financial Efficiency
Return on equity (ROE) is -167.97% and return on invested capital (ROIC) is -107.05%.
| Return on Equity (ROE) | -167.97% |
| Return on Assets (ROA) | -87.70% |
| Return on Invested Capital (ROIC) | -107.05% |
| Return on Capital Employed (ROCE) | -655.57% |
| Weighted Average Cost of Capital (WACC) | 20.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$28.67M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Skye Bioscience has paid $3,400 in taxes.
| Income Tax | 3,400 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.57% in the last 52 weeks. The beta is 2.93, so Skye Bioscience's price volatility has been higher than the market average.
| Beta (5Y) | 2.93 |
| 52-Week Price Change | -81.57% |
| 50-Day Moving Average | 0.80 |
| 200-Day Moving Average | 1.25 |
| Relative Strength Index (RSI) | 40.31 |
| Average Volume (20 Days) | 186,435 |
Short Selling Information
The latest short interest is 1.13 million, so 3.20% of the outstanding shares have been sold short.
| Short Interest | 1.13M |
| Short Previous Month | 1.27M |
| Short % of Shares Out | 3.20% |
| Short % of Float | 4.90% |
| Short Ratio (days to cover) | 6.69 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -59.08M |
| Pretax Income | -57.33M |
| Net Income | -57.33M |
| EBITDA | -58.36M |
| EBIT | -59.08M |
| Earnings Per Share (EPS) | -$1.45 |
Balance Sheet
The company has $17.11 million in cash and $311,318 in debt, with a net cash position of $16.80 million or $0.48 per share.
| Cash & Cash Equivalents | 17.11M |
| Total Debt | 311,318 |
| Net Cash | 16.80M |
| Net Cash Per Share | $0.48 |
| Equity (Book Value) | 9.01M |
| Book Value Per Share | 0.26 |
| Working Capital | 8.16M |
Cash Flow
| Operating Cash Flow | -42.43M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 718,859 |
| Net Borrowing | -71,525 |
| Free Cash Flow | -42.43M |
| FCF Per Share | -$1.21 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Skye Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.69% |
| Shareholder Yield | -0.69% |
| Earnings Yield | -239.94% |
| FCF Yield | -177.60% |
Analyst Forecast
The average price target for Skye Bioscience is $7.71, which is 985.92% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.71 |
| Price Target Difference | 985.92% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 1:250.
| Last Split Date | Sep 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:250 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |